解鎖阿爾茨海默?。ˋD）靶點(diǎn)密碼開啟靶向治療新篇章

解鎖阿爾茨海默?。ˋD）靶點(diǎn)密碼，開啟靶向治療新篇章前言：阿爾茨海默?。ˋD）是一種嚴(yán)重的神經(jīng)退行性疾病，多發(fā)于高齡人群，主要表現(xiàn)為記憶、思維、分析判斷、視空間辨認(rèn)、情緒等障礙。從實(shí)驗(yàn)室到臨床應(yīng)用的過程充滿挑戰(zhàn)。阿爾茨海默癥新型療法的開發(fā)主要聚焦于靶向Aβ、tau、神經(jīng)炎癥和突觸保護(hù)等。AD相關(guān)重組蛋白在推動藥物發(fā)現(xiàn)和破譯靶點(diǎn)相互作用中發(fā)揮重要作用。義翹神州提供AD相關(guān)的高品質(zhì)藥物靶點(diǎn)重組蛋白及抗體產(chǎn)品，支持AD疾病診斷研究和藥物研發(fā)。AD相關(guān)靶點(diǎn)：AD的病理變化包括胞外淀粉樣蛋白β（Aβ）沉積形成淀粉樣斑塊、Tau蛋白過度磷酸化形成神經(jīng)元纖維纏結(jié)（NFT）、神經(jīng)炎癥、神經(jīng)元丟失、突觸障礙等。AD的常見生物標(biāo)志物包括淀粉樣前體蛋白（APP）、微管相關(guān)蛋白（Tau）、NGF、CASP9、CLU、AGER、DPYSL2、PNMT、BDNF、GSK3B、ApoE、GLP-1R、BACE1等。這些生物標(biāo)志物在AD生理和病理過程發(fā)揮著關(guān)鍵作用。比如，NGF、DPYSL2維持神經(jīng)細(xì)胞的生長。CASP9對細(xì)胞程序性死亡（凋亡）和組織穩(wěn)態(tài)至關(guān)重要。CLU、GSK3B可調(diào)節(jié)各種細(xì)胞功能。AGER在病理狀態(tài)下會誘發(fā)炎癥和氧化應(yīng)激。PNMT與壓力相關(guān)激素（如腎上腺素）的合成相關(guān)。BDNF支持神經(jīng)元的存活和可塑性。BACE1與AD中Aβ的產(chǎn)生相關(guān)，是AD治療的重要靶點(diǎn)之一。GLP1R激動劑已被證明在抗神經(jīng)炎癥、減輕氧化應(yīng)激和神經(jīng)營養(yǎng)等方面發(fā)揮重要作用，已成為治療AD的潛在藥物。AD蛋白在研究中的應(yīng)用：高品質(zhì)重組蛋白（如APP、Tau、ApoE等）已應(yīng)用于AD藥物研發(fā)，能夠促進(jìn)機(jī)理研究和臨床前評估，從而推動AD創(chuàng)新療法的開發(fā)。Gao團(tuán)隊(duì)利用重組GSK-3β蛋白（貨號：10044-H07B）驗(yàn)證了GSK-3β與PKG之間的相互作用，發(fā)現(xiàn)IcarisideII通過干擾PKG/GSK-3β/自噬軸減輕腦損傷。Endicott團(tuán)隊(duì)利用重組Tau蛋白（貨號：10058-H07E）和蛋白酶抑制劑處理溶酶體，發(fā)現(xiàn)經(jīng)buparlisib或pictilisib處理的小鼠肝溶酶體對CMA底物Tau的吸收增強(qiáng)。Sperling團(tuán)隊(duì)利用重組AChE蛋白（貨號：50543-M08H）研究發(fā)現(xiàn)與laminin-1結(jié)合會導(dǎo)致神經(jīng)元生長。Zhang團(tuán)隊(duì)利用重組APP或BACE1蛋白（義翹神州）研究發(fā)現(xiàn)與氧化石墨烯（GO）納米顆粒的相互作用，可降低小鼠體內(nèi)的Aβ水平并改善其記憶力。Vojdani團(tuán)隊(duì)利用重組β-NGF和BDNF蛋白（義翹神州）發(fā)現(xiàn)與抗Aβ-42肽抗體高度反應(yīng)。用于表面等離子體共振SPR檢測將不同濃度的PKG與GSK-3β（貨號：10044-H07B，義翹神州）結(jié)合，利用表面等離子體共振（SPR）技術(shù)測定結(jié)合親和力。Doi:10.1111/bph.14912用于CMA底物檢測與對照組相比，經(jīng)buparlisib或pictilisib處理的小鼠肝溶酶體對CMA底物Tau（貨號：10058-H07E，義翹神州）的攝取增加，GFAP磷酸化減少。Doi:10.1083/jcb.202001031用于免疫染色抗(His)6

Tag抗體（綠色）對(His)6

TagE6-AChE（貨號：50543-M08H，義翹神州）處理過的R28細(xì)胞進(jìn)行免疫染色。細(xì)胞核用DAPI（藍(lán)色）染色。Doi:10.1371/journal.pone.0036683用于WB檢測通過WB檢測GO/BGO與

APP或BACE1（義翹神州）的相互作用。S和P分別指沉淀得到的上清液和沉淀顆粒。Doi:10.7150/thno.50616用于ELISA檢測通過ELISA方法測定對照組和AD血清中的抗體水平。針對各種蛋白質(zhì)和肽的IgG抗體，包括

β-NGF和BDNF（義翹神州），都與AD有關(guān)。Doi:10.1155/2018/1672568?義翹神州AD特色產(chǎn)品：義翹神州的產(chǎn)品已支持多篇文章發(fā)表在國內(nèi)外學(xué)術(shù)期刊，涉及到的產(chǎn)品有重組蛋白、抗體、ELISA試劑、基因等。HumanGLP1RProtein(His&AVITag)(Cat:13944-H49H-B)Purity:≥95%determinedbySEC-HPLCandSDS.

HumanGSK3BProtein(HisTag)(Cat:10044-H07B)（助力4篇文章發(fā)表）ImmobilizedHis-GSK3BcanbindtobiotinylatedhumanHG3C-CTNNB1Anti-ClusterinAntibody,MousemAb(Cat:11297-MM01)（應(yīng)用：WB、ELISA、FCM、ICC/IF）ImmunofluorescencestainingofHumanCLUinHelacells.Anti-ApoEAntibody,RabbitpAb(Cat:10817-RP02)助力4篇文章發(fā)表，應(yīng)用：ELISA、IHC-P【參考文獻(xiàn)】1.HusnaIbrahim,N.etal.PharmacotherapyofAlzheimer’sDisease:SeekingClarityinaTimeofUncertainty.FrontiersinPharmacologyvol.11Preprintat/10.3389/fphar.2020.00261(2020).2.Hansson,O.etal.TheAlzheimer’sAssociationappropriateuserecommendationsforbloodbiomarkersinAlzheimer’sdisease.Alzheimer’sandDementiavol.182669–2686Preprintat/10.1002/alz.12756(2022).3.TahamiMonfared,etal.Alzheimer’sDisease:EpidemiologyandClinicalProgression.NeurologyandTherapyvol.11553–569Preprintat/10.1007/s40120-022-00338-8(2022).4.Seibert,M.etal.EfficacyandsafetyofpharmacotherapyforAlzheimer’sdiseaseandforbehaviouralandpsychologicalsymptomsofdementiainolderpatientswithmoderateandseverefunctionalimpairments:asystematicreviewofcontrolledtrials.AlzheimersResTher13,(2021).5.Bai,B.etal.ProteomiclandscapeofAlzheimer’sDisease:novelinsightsintopathogenesisandbiomarkerdiscovery.MolecularNeurodegenerationvol.16Preprintat/10.1186/s13024-021-00474-z(2021).6.Sperling,etal.MouseacetylcholinesteraseenhancesneuriteoutgrowthofratR28cellsthroughinteractionwithlaminin-1.PLoSOne7,(2012).7.vanDyck,C.H.etal.LecanemabinEarlyAlzheimer’sDisease.NewEnglandJournalofMedicine388,9–21(2023).8.Vaz,M.,etal.RoleofAducanumabintheTreatmentofAlzheimer’sDisease:ChallengesandOpportunities.ClinicalInterventionsinAgingvol.17797–810Preprintat/10.2147/CIA.S325026(2022).9.Hampel,H.etal.TheAmyloid-βPathwayinAlzheimer’sDisease.MolecularPsychiatryvol.265481–5503Preprintat/10.1038/s41380-021-01249-0(2021).10.Husain,M.A.,Laurent,B.&Plourde,M.APOEandAlzheimer’sDisease:FromLipidTransporttoPhysiopathologyandTherapeutics.FrontiersinNeurosciencevol.15Preprintat/10.3389/fnins.2021.630502(2021).11.Milà-Alomà,M.etal.Plasmap-tau231andp-tau217asstatemarkersofamyloid-βpathologyinpreclinicalAlzheimer’sdisease.NatMed28,1797–1801(2022).12.Li,Q.X.etal.GLP-1andUnderlyingBeneficialActionsinAlzheimer’sDisease,Hypertension,andNASH.FrontiersinEndocrinologyvol.12Preprintat/10.3389/fendo.2021.721198(2021).13.Amadoro,G.etal.NerveGrowthFactor-BasedTherapyinAlzheimer’sDiseaseandAge-RelatedMacularDegeneration.FrontiersinNeurosciencevol.15Preprintat/10.3389/fnins.2021.735928(2021).14.Rohn,etal.Immunohistochemicalanalysisofcaspaseexpressioninthebrainsofindividualswithobesityoroverweight.Neurobiologyofdisease11(2),341-354(2002).15.1Foster,etal.ClusterininAlzheimer’sdisease:Mechanisms,genetics,andlessonsfromotherpathologies.FrontiersinNeurosciencevol.13Preprintat/10.3389/fnins.2019.00164(2019).16.Bennet,A.M.etal.GeneticassociationofsequencevariantsnearAGER/NOTCH4anddementia.JournalofAlzheimer’sDisease24,475–484(2011).17.Noura,M.etal.PivotalroleofDPYSL2AinKLF4-mediatedmonocyticdifferentiationofacutemyeloidleukemiacells.SciRep10,(2020).Henjum,K.etal.CerebrospinalfluidcatecholaminesinAlzheimer’sdiseasepatientswithandwithoutbiologicaldisease.TranslPsychiatry12,(2022).18.Lauretti,E.,Dincer,O.&Praticò,D.Glycogensynthasekinase-3signalinginAlzheimer’sdisease.BiochimicaetBiophysicaActa-MolecularCellResearchvol.1867Preprintat/10.1016/j.bbamcr.2020.118664(2020).19.Gao,J.etal.IcarisideII,aphosphodiesterase5inhibitor,attenuatescerebralischaemia/reperfusioninjurybyinhibitingglycogensynthasekinase-3β-mediatedactivationofautophagy.BrJPharmacol177,1434–1452(2020).20.Hampel,H.etal.Theβ-SecretaseBACE1inAlzheimer’sDisease.BiologicalPsychiatryvol.89745–756Preprintat/10.1016/j.b